|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"yen c j"
Showing items 1-25 of 471 (19 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
|
Ren, Z.;Ducreux, M.;Abou-Alfa, G.K.;Merle, P.;Fang, W.;Edeline, J.;Li, Z.;Wu, L.;Assenat, E.;Hu, S.;Rimassa, L.;Zhang, T.;Blanc, J.-F.;Pan, H.;Ross, P.;Yen, C.-J.;Tran, A.;Shao, G.;Bouattour, M.;Chen, Y.;Meyer, T.;Hou, J.;Tougeron, D.;Bai, Y.;Hou, M.-M.;Meng, Z.;Wu, J.;Li, V.;Chica-Duque, S.;Cheng, A.-L. |
| 國立成功大學 |
2023 |
The impact of preoperative waiting time in Stage II–III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen, C.-C.;Yang, Yang Y.-H.;Ku, H.-Y.;Hu, Hu H.-M.;Lo, S.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Yen, C.-J.;Chen, L.-T.;Shan, Y.-S. |
| 國立成功大學 |
2023 |
Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study
|
Hsu, C.;Chang, Y.-F.;Yen, C.-J.;Xu, Y.-W.;Dong, M.;Tong, Y.-Z. |
| 國立成功大學 |
2023 |
ASO Visual Abstract: Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment
|
Lin, Y.-H.;Hsiao, J.-R.;Wu, Y.-H.;Chang, J.S.;Ou, C.-Y.;Lee, W.-T.;Huang, C.-C.;Chang, Chang C.-C.;Lai, Y.-H.;Tsai, S.-T.;Hsueh, W.-T.;Yen, C.-J.;Lin, C.-L.;Chen, Y.-S.;Jiang, S.-S.;Su, Y.-C.;Wu, S.-Y. |
| 國立成功大學 |
2023 |
Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways
|
Chen, Y.-T.;Masbuchin, A.N.;Fang, Y.-H.;Hsu, L.-W.;Wu, S.-N.;Yen, C.-J.;Liu, Y.-W.;Hsiao, Y.-W.;Wang, J.-M.;Rohman, M.S.;Liu, P.-Y. |
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 國立成功大學 |
2023 |
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma The JUPITER-02 Randomized Clinical Trial
|
Mai, H.-Q.;Chen, Q.-Y.;Chen, D.;Hu, C.;Yang, K.;Wen, J.;Li, J.;Shi, Y.;Jin, F.;Xu, R.;Pan, J.;Qu, S.;Li, P.;Hu, C.;Liu, Y.-C.;Jiang, Y.;He, X.;Wang, H.-M.;Lim, W.-T.;Liao, W.;He, X.;Chen, X.;Wang, S.;Yuan, X.;Li, Q.;Lin, X.;Jing, S.;Chen, Y.;Lu, Y.;Hsieh, C.-Y.;Yang, M.-H.;Yen, C.-J.;Samol, J.;Luo, X.;Wang, X.;Tang, X.;Feng, H.;Yao, S.;Keegan, P.;Xu, R.-H. |
| 臺大學術典藏 |
2022-09-20T06:49:39Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; Chang K.-J.; Chang C.-C.; Yu Y.-H.; Lin L.-Y.; HWANG, JUEY-JEN |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-09-15T01:08:51Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Chia-Chi Lin; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; Hsu C. |
| 臺大學術典藏 |
2022-09-15T01:08:49Z |
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
|
Shiah H.-S.; Chiang N.-J.; Chia-Chi Lin; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. |
| 臺大學術典藏 |
2022-09-06T02:42:47Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; Chang K.-J.; Chang C.-C.; Yu Y.-H.; LIAN-YU LIN; Hwang J.-J. |
| 臺大學術典藏 |
2022-08-19T00:20:47Z |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma
|
Tak W.Y.; Yen C.-J.; Jeffers M.; Krissel H.; Kappeler C.; Rajagopalan P.; Hsieh W.-S.; Tay M.H.; Yeo W.; Park J.-W.; Poon R.T.P.; Rau K.-M.; CHIUN HSU; Yoon J.-H.; Lin C.-Y.; Choi H.J.; Heo J.; Lim H.Y. |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study
|
Lin C.-C.; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU |
| 臺大學術典藏 |
2022-08-12T06:27:51Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; KING-JEN CHANG; Chang C.-C.; Yu Y.-H.; Lin L.-Y.; Hwang J.-J. |
| 臺大學術典藏 |
2022-06-10T06:11:05Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:00Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; ZHONG-ZHE LIN; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
|
Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-05-09T08:46:35Z |
Sequence variants of peroxisome proliferator-activated receptor-gamma gene and the clinical courses of patients with end-stage renal disease
|
Chao C.-T.; YEN-CHING CHEN; Chiang C.-K.; Huang J.-W.; Hu F.-C.; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-05-09T08:46:33Z |
Interplay between Superoxide Dismutase, Glutathione Peroxidase, and Peroxisome Proliferator Activated Receptor Gamma Polymorphisms on the Risk of End-Stage Renal Disease among Han Chinese Patients
|
Chao C.-T.; YEN-CHING CHEN; Chiang C.-K.; Huang J.-W.; Fang C.-C.; Chang C.-C.; Yen C.-J. |
| 臺大學術典藏 |
2022-05-09T08:46:30Z |
Effect of Kidney Dysfunction on Cerebral Cortical Thinning in Elderly Population
|
Chen C.-H.; Chen Y.-F.; Chiu M.-J.; Chen T.-F.; Tsai P.-H.; Chen J.-H.; Yen C.-J.; Tang S.-C.; Yeh S.-J.; YEN-CHING CHEN |
Showing items 1-25 of 471 (19 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
